Skin cancer – Squamous cell carcinoma

Published on 04/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 910 times

Skin cancer – Squamous cell carcinoma

Squamous cell carcinoma (SCC) is a heterogeneous disease comprising clinically distinct but histologically similar entities with differing risk factors implicated in their aetiopathogenesis.

Bowen’s disease (in situ squamous cell carcinoma)

Bowen’s disease is common and typically occurs on the lower leg in elderly women. The lesions are solitary or multiple. Previous exposure to arsenicals predisposes to the condition.

Pink or lightly pigmented scaly plaques, up to several centimetres in size, are found on the lower leg or trunk (Fig. 1). Transformation into invasive squamous cell carcinoma is infrequent. Bowen’s disease may resemble discoid eczema, psoriasis or superficial basal cell carcinoma. Histologically, the epidermis is thickened and the keratinocytes are atypical, but not invasive. Small biopsy samples may not be representative of the entire lesion and if there is clinical doubt then larger or excisional biopsies should be undertaken.

Bowen’s disease is treated by cryotherapy, curettage, excision, topical 5-fluorouracil or imiquimod, or photodynamic therapy (p. 113).

Keratoacanthoma

A keratoacanthoma is a rapidly growing tumour usually arising in the sun-exposed skin of the face or arms (Fig. 2). A keratoacanthoma is now generally considered a low-risk SCC, but was previously not regarded as malignant and may resolve spontaneously leaving a prominent scar. The tumour grows rapidly over a few weeks into a dome-shaped nodule up to 2 cm in diameter. There is often a keratin plug, which may fall out to leave a crater.

Histologically, a keratoacanthoma resembles an SCC, although it shows more symmetry and shouldering. Excision is the preferred treatment, but thorough curettage and cautery will usually be satisfactory. If recurrence occurs after curettage, excision is recommended.

Squamous cell carcinoma

Squamous cell carcinoma is a malignant tumour arising from keratinocytes of the epidermis or hair follicle and is the second most common skin cancer. The incidence of SCC is thought to be approximately a quarter that of basal cell carcinoma (BCC), affecting 2 per 1000 population per annum. SCC mainly occurs in white-skinned people over 55 years of age, is three times more common in males than in females and may metastasize.

Clinical presentation

Squamous cell carcinomas usually develop in sun-exposed sites such as the face, neck, forearm or hand (Fig. 3). Commonly other signs of photodamage will be evident in adjacent skin: solar elastosis, hyperkeratosis, mottled pigmentation and telangiectasia. Premalignant changes such as actinic keratoses and Bowen’s disease as well as other skin cancers may also be present. On mucous membranes, leukokeratosis and fissuring or actinic chelosis are frequent. Lesions present in a variety of ways:

The tumour may start within an actinic keratosis as a small papule that, if left, progresses to ulcerate and form a crust. This type of SCC does not commonly metastasize. Ulcerating forms of SCC which develop at the edge of ulcers (Fig. 5), in scars and at sites of radiation damage are frequently more aggressive. Metastasis is found in 10% or more of these cancers. An important clinical marker of SCC is its rapidity of growth. Most patients will report a lesion that grows over several months, in contrast to a BCC which would frequently develop slowly over 6 or more months. Tenderness is also an important symptom identified in SCCs and is thought to represent the extension of the SCC around nerves.

Management

Surgical excision is the treatment of choice. Large lesions may require a skin graft. In the elderly, SCCs of the face or scalp can be treated by radiotherapy (after an incisional biopsy for histological diagnosis). SCCs can be subdivided into high risk and low risk of recurrence or metastasis, although the exact boundaries are somewhat controversial. Generally agreed features of a high-risk SCC are given in the Box. Patients are examined for lymph node metastasis at presentation: suspicious nodes are biopsied. Carefully agreed follow-up, especially for high-risk SCCs, is recommended.